

Displayed as: Multiple Sclerosis Adherence Adherence to Non-Infused
Disease-Modifying Agents
Used to Treat Multiple Sclerosis
Measure (Specialty)

Description

- This measure is part of the Specialty Core Set developed by the Pharmacy Quality Alliance (PQA)
- Performance is calculated using the proportion of days covered (PDC) methodology to assess the adherence of patients over the age of 18 for noninfused medications treating multiple sclerosis
- The treatment period begins on the first date of the initial fill and extends through the end of the measurement period

Y

Did You Know?

- The financial burden on patients with multiple sclerosis can increase as disability gradually changes*
- The average annual cost for multiple sclerosis treatment ranges from \$30,000 to \$100,000 annually*
- Multiple sclerosis most commonly affects women ages 30-45**
- Currently, there is no cure available for the disease
- Patients adherent to therapy will benefit from slower disease progression and may decrease the frequency of relapses

Calculation

NUMERATOR =

Number of patients who have 80% or more days covered by medication during the measurement period

DENOMINATOR =

Patients who receive two or more prescriptions for a non-infused disease modifying agent used to treat multiple sclerosis with a total day supply of 56 or more days during the measurement period

Exclusions

- Patients with prescription claims for infused disease modifying agents
- Patients starting therapy with a non-infused disease modifying agent during the last 91 days of the measurement period

Therapeutic Categories Include:

Oral or self-administered (including but not limited to)

Beta-interferons Glatiramer acetate Dimethyl fumarate



*The American Journal of Managed Care -

https://www.ajmc.com/journals/supplement/2016/cost-effectiveness-multiple-sclerosis/cost-effectiveness-multiple-sclerosis-economic-burden

**National Multiple Sclerosis Society -

https://www.nationalmssociety.org/What-is-MS